Single agent daratumumab has shown clinical activity in relapsed, refractory multiple myeloma (RRMM). The Intergroupe Francophone du Myélome 2014-04 trial was designed to further investigate daratumumab in combination with dexamethasone in triple RRMM patients. Patients received daratumumab infusions in combination with weekly dexamethasone until disease progression or unacceptable toxicity. Fifty-seven patients were included in the trial and evaluable for response. The overall response rate and the clinical benefit rate were 33% (n = 19) and 48% (n = 27), respectively. Five (8·8%) patients achieved a very good partial response or better. The median time to response was 4 weeks. For responding patients, the median progression-free survival was 6·6 months, compared to 3·7 months (3·0–5·5) for those with a minimal or stable disease. The median overall survival (OS) for all patients was 16·7 months (11·2–24·0). For responding patients, the median OS was 23·23 months, whereas that of patients with progressive disease was 2·97 months. The incidence of infusion-related reactions was 37%; all cases were manageable and did not lead to dose reduction or permanent treatment discontinuation. These data demonstrate that treatment with daratumumab and dexamethasone results in a meaningful long-term benefit with an acceptable safety profile for patients with triple RRMM.

Supporting Information

References

Aaronson, N.K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N.J., Filiberti, A., Flechtner, H., Fleishman, S.B. & de Haes, J.C. (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85, 365–376.
10.1093/jnci/85.5.365
CAS PubMed Web of Science® Google Scholar
Bladé, J., Samson, D., Reece, D., Apperley, J., Björkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. & Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British Journal of Haematology, 102, 1115–1123.
10.1046/j.1365-2141.1998.00930.x
CAS PubMed Web of Science® Google Scholar
Chari, A., Suvannasankha, A., Fay, J.W., Arnulf, B., Kaufman, J.L., Ifthikharuddin, J.J., Weiss, B.M., Krishnan, A., Lentzsch, S., Comenzo, R., Wang, J., Nottage, K., Chiu, C., Khokhar, N.Z., Ahmadi, T. & Lonial, S. (2017) Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood, 130, 974–981.
10.1182/blood-2017-05-785246
CAS PubMed Web of Science® Google Scholar
Chatterjee, S., Daenthanasanmak, A., Chakraborty, P., Wyatt, M.W., Dhar, P., Selvam, S.P., Fu, J., Zhang, J., Nguyen, H., Kang, I., Toth, K., Al-Homrani, M., Husain, M., Beeson, G., Ball, L., Helke, K., Husain, S., Garrett-Mayer, E., Hardiman, G. & Mehrotra, M. (2018) CD38-NAD+Axis regulates immunotherapeutic anti-tumor T cell response. Cell Metabolism, 27, 85–100.e8.
10.1016/j.cmet.2017.10.006
CAS PubMed Web of Science® Google Scholar
CRAN (2018) The Comprehensive R Archive Network. Available at: https://cran.r-project.org/ [Accessed July 19, 2018].
Google Scholar
Dimopoulos, M. (2018) Results from a phase II study of isatuximab as a single agent and in combination with dexamethasone in patients with relapsed/refractory multiple myeloma. Blood, 132, 155.
10.1182/blood-2018-155
Web of Science® Google Scholar
van de Donk, N.W.C.J., Otten, H.G., El Haddad, O., Axel, A., Sasser, A.K., Croockewit, S. & Jacobs, J.F.M. (2016) Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA). Clinical Chemistry and Laboratory Medicine, 54, 1105–1109.
PubMed Web of Science® Google Scholar
Durie, B.G.M., Harousseau, J.-L., Miguel, J.S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Cavo, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G. & Rajkumar, S.V.; for the International Myeloma Working Group (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, 1467–1473.
10.1038/sj.leu.2404284
CAS PubMed Web of Science® Google Scholar
Krejcik, J., Casneuf, T., Nijhof, I.S., Verbist, B., Bald, J., Plesner, T., Syed, K., Liu, K., van de Donk, N.W.C.J., Weiss, B.M., Ahmadi, T., Lokhorst, H.M., Mutis, T. & Sasser, A.K. (2016) Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood, 128, 384–394.
10.1182/blood-2015-12-687749
CAS PubMed Web of Science® Google Scholar
Kumar, S.K., Lee, J.H., Lahuerta, J.J., Morgan, G., Richardson, P.G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., LeLeu, X., Hulin, C., Klein, S.K., Sonneveld, P., Siegel, D., Bladé, J., Goldschmidt, H., Jagannath, S., Miguel, J.S., Orlowski, R., Sutherland, H.J., Bladé, J., Scott, E.C., Oriol, A., Berdeja, J., Gharibo, M., Stevens, D.A., LeBlanc, R., Sebag, M., Callander, N., Jakubowiak, A., White, D., de la Rubia, J., Richardson, P.G., Lisby, S., Feng, H., Uhlar, C.M., Khan, I., Ahmadi, T. & Voorhees, P.M. (2012) Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia, 26, 149–157.
10.1038/leu.2011.196
CAS PubMed Web of Science® Google Scholar
Lokhorst, H.M., Plesner, T., Laubach, J.P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M.C., Lassen, U., Krejcik, J., Palumbo, A., van de Donk, N.W.C.J., Ahmadi, T., Khan, I., Uhlar, C.M., Wang, J., Sasser, A.K., Losic, N., Lisby, S., Basse, L., Brun, N. & Richardson, P.G. (2015) Targeting CD38 with daratumumab monotherapy in multiple myeloma. The New England Journal of Medicine, 373, 1207–1219.
10.1056/NEJMoa1506348
CAS PubMed Web of Science® Google Scholar
Lonial, S., Weiss, B.M., Usmani, S.Z., Singhal, S., Chari, A., Bahlis, N.J., Belch, A., Krishnan, A., Vescio, R.A., Mateos, M.V., Mazumder, A., Orlowski, R.Z., Sutherland, H.J., Bladé, J., Scott, E.C., Oriol, A., Berdeja, J., Gharibo, M., Stevens, D.A., LeBlanc, R., Sebag, M., Callander, N., Jakubowiak, A., White, D., de la Rubia, J., Richardson, P.G., Lisby, S., Feng, H., Uhlar, C.M., Khan, I., Ahmadi, T. & Voorhees, P.M. (2016) Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. The The Lancet, 387, 1551–1560.
10.1016/S0140-6736(15)01120-4
CAS PubMed Web of Science® Google Scholar
Marlein, C.R., Piddock, R.E., Mistry, J.J., Zaitseva, L., Hellmich, C., Horton, R.H., Zhou, Z., Auger, M.J., Bowles, K.M. & Rushworth, S.A. (2019) CD38-Driven Mitochondrial Trafficking Promotes Bioenergetic Plasticity in Multiple Myeloma. Cancer Research. Available at: http://cancerres.aacrjournals.org/content/early/2019/03/30/0008-5472.CAN-18-0773 [Accessed April 17, 2019].
10.1158/0008-5472.CAN-18-0773
PubMed Web of Science® Google Scholar
Nooka, A.K., Kastritis, E., Dimopoulos, M.A. & Lonial, S. (2015) Treatment options for relapsed and refractory multiple myeloma. Blood, 125, 3085–3099.
10.1182/blood-2014-11-568923
CAS PubMed Web of Science® Google Scholar
Phipps, C., Chen, Y., Gopalakrishnan, S. & Tan, D. (2015) Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development. Therapeutic Advances in Hematology, 6, 120–127.
10.1177/2040620715572295
CAS PubMed Web of Science® Google Scholar
Rabin, R. & de Charro, F. (2001) EQ-5D: a measure of health status from the EuroQol Group. Annals of Medicine, 33, 337–343.
10.3109/07853890109002087
CAS PubMed Web of Science® Google Scholar
Röllig, C., Knop, S. & Bornhäuser, M. (2015) Multiple myeloma. The Lancet, 385, 2197–2208.
10.1016/S0140-6736(14)60493-1
CAS PubMed Web of Science® Google Scholar
Stead, M.L., Brown, J.M., Velikova, G., Kaasa, S., Wisløff, F., Child, J.A., Hippe, E., Hjorth, M., Sezer, O. & Selby, P. (1999) Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life. British Journal of Haematology, 104, 605–611.
10.1046/j.1365-2141.1999.01206.x
CAS PubMed Web of Science® Google Scholar
Tang, F., Malek, E., Math, S., Schmotzer, C.L. & Beck, R.C. (2018) Interference of therapeutic monoclonal antibodies with routine serum protein electrophoresis and immunofixation in patients with myeloma: frequency and duration of detection of daratumumab and elotuzumab. American Journal of Clinical Pathology, 150, 121–129.
10.1093/ajcp/aqy037
CAS PubMed Web of Science® Google Scholar
U S Food and Drug Administration Home Page (2015) Available at: https://www.fda.gov/ [Accessed July 19, 2018].
Google Scholar
Usmani, S.Z., Weiss, B.M., Plesner, T., Bahlis, N.J., Belch, A., Lonial, S., Lokhorst, H.M., Voorhees, P.M., Richardson, P.G., Chari, A., Sasser, A.K., Axel, A., Feng, H., Uhlar, C.M., Wang, J., Khan, I., Ahmadi, T. & Nahi, H. (2016) Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood, 128, 37–44.
10.1182/blood-2016-03-705210
CAS PubMed Web of Science® Google Scholar
Usmani, S.Z., Diels, J., Ito, T., Mehra, M., Khan, I. & Lam, A. (2017) Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison. American Journal of Hematology, 92, E146–E152.
10.1002/ajh.24781
CAS PubMed Web of Science® Google Scholar
de Weers, M., Tai, Y.-T., van der Veer, M.S., Bakker, J.M., Vink, T., Jacobs, D.C.H., Oomen, L.A., Peipp, M., Valerius, T., Slootstra, J.W., Mutis, T., Bleeker, W.K., Anderson, K.C., Lokhorst, H.M., van de Winkel, J.G.J. & Parren, P.W.H.I. (2011) Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. Journal of Immunology, 186, 1840–1848.
10.4049/jimmunol.1003032
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume187, Issue3

November 2019

Pages 319-327

Filename	Description
bjh16059-sup-0001-DataS1.docxWord document, 1.6 MB	Data S1. Supplemental results.
bjh16059-sup-0002-DataS2.pdfPDF document, 2 MB	Data S2. A Multicentre Open label Phase II study of Daratumumab in Combination with Dexamethasone in Multiple Myeloma resistant or refractory to Bortezomib and Lenalidomide and Pomalidomide – the IFM 2014-04 study.

Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial

Summary

Supporting Information

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial

Summary

Supporting Information

References

Citing Literature

References

Related

Information